A61K38/08

B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

COLLAGEN PRODUCTION
20230002448 · 2023-01-05 ·

The present invention provides a method for increasing collagen production in a cell and a method for inhibiting cell migration. Further, the present invention provides a pharmaceutical composition comprising lipopeptides, wherein the lipopeptides substantially consist of ETTES lipopeptides, and uses of said pharmaceutical composition. The invention also provides a supramolecular structure comprising lipopeptides, wherein the lipopeptides substantially consist of ETTES lipopeptides, as well as a method for producing said supramolecular structure. The supramolecular structure of the invention may be used in the method for increasing collagen production and/or method for inhibiting cell migration.

A HYPERTENSION ANIMAL MODEL AND METHODS OF USE
20230233713 · 2023-07-27 ·

The invention is directed to a hypertension animal model, and methods of using the same to induce heart failure with preserved ejection fraction (HFpEF) responses.

Monoclonal antibodies against HER2 epitope and methods of use thereof

This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.

Monoclonal antibodies against HER2 epitope and methods of use thereof

This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.

Compositions and methods for combinatorial drug discovery in nanoliter droplets

Compositions and methods for combinatorial drug discovery in nanoliter droplets are described. Novel synergistic agents that increase efficacy of antibiotic agents to treat bacterial infection are disclosed.

Compositions and methods for combinatorial drug discovery in nanoliter droplets

Compositions and methods for combinatorial drug discovery in nanoliter droplets are described. Novel synergistic agents that increase efficacy of antibiotic agents to treat bacterial infection are disclosed.

Compositions and methods for combinatorial drug discovery in nanoliter droplets

Compositions and methods for combinatorial drug discovery in nanoliter droplets are described. Novel synergistic agents that increase efficacy of antibiotic agents to treat bacterial infection are disclosed.

Use of GHRP-6 as late cardioprotective and cardiac restoration medicament

The present invention is related to the use of the growth hormone releasing peptide-6 (GHRP-6) for the manufacture of a late cardioprotective and cardiac restoration medicament. Said late cardioprotective and cardiac restoration medicament comprises GHRP-6 and a pharmaceutically acceptable excipient or vehicle. It also provides a method for the treatment of a disease that involves a low cardiac output, wherein a therapeutically effective amount of a late cardioprotective and cardiac restoration medicament comprising GHRP-6 is administered to a subject in need. Said medicament allows treating in a late manner, even days later, the myocardium that suffered episodes of stunning, hibernation, ischemia and its consequences thereof.